p53 codon 72 polymorphism and hematological cancer risk: an update meta-analysis.
BACKGROUND: Previous studies on the association of p53 codon 72 (Arg72Pro) polymorphism with hematological malignancies risk have produced conflicting results. The purpose of this meta-analysis is to define the effect of p53 Arg72Pro polymorphism on hematological malignancies risk. METHODOLOGY/PRINC...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2012-01-01
|
| Series: | PLoS ONE |
| Online Access: | http://europepmc.org/articles/PMC3454327?pdf=render |
| _version_ | 1818358658296184832 |
|---|---|
| author | Yu Weng Liqin Lu Guorong Yuan Jing Guo Zhizhong Zhang Xinyou Xie Guangdi Chen Jun Zhang |
| author_facet | Yu Weng Liqin Lu Guorong Yuan Jing Guo Zhizhong Zhang Xinyou Xie Guangdi Chen Jun Zhang |
| author_sort | Yu Weng |
| collection | DOAJ |
| description | BACKGROUND: Previous studies on the association of p53 codon 72 (Arg72Pro) polymorphism with hematological malignancies risk have produced conflicting results. The purpose of this meta-analysis is to define the effect of p53 Arg72Pro polymorphism on hematological malignancies risk. METHODOLOGY/PRINCIPAL FINDINGS: Through searching PubMed databases (or hand searching) up to April 2012 using the following MeSH terms and keywords: "p53", "codon 72" "polymorphism" and "leukemia", or "lymphoma", or "myeloma", thirteen were identified as eligible articles in this meta-analysis for p53 Arg72Pro polymorphism (2,731 cases and 7, 356 controls), including nine studies on leukemia (1,266 cases and 4, 474 controls), three studies on lymphoma (1,359 cases and 2,652 controls), and one study on myeloma. The overall results suggested that p53 Arg72Pro polymorphism was not associated with hematological malignancies risk. In stratified analyses, significantly increased non-Hodgkin lymphomas risk was found in p53 Arg72Pro polymorphism heterozygote model (Arg/Pro vs. Arg/Arg: OR = 1.18, 95%CI: 1.02-1.35) and dominant model (Arg/Pro+Pro/Pro vs. Arg/Arg: OR = 1.18, 95%CI: 1.03-1.34), but no significant association was found between leukemia risk and p53 Arg72Pro polymorphism. Further studies showed no association between leukemia risk and p53 Arg72Pro polymorphism when stratified in subtypes of leukemias, ethnicities and sources of controls. CONCLUSIONS/SIGNIFICANCE: This meta-analysis indicates that the p53 Arg72Pro polymorphism may contribute to susceptibility to non-Hodgkin lymphomas. |
| first_indexed | 2024-12-13T20:32:30Z |
| format | Article |
| id | doaj.art-d17db0a839c247359de78f3b91784018 |
| institution | Directory Open Access Journal |
| issn | 1932-6203 |
| language | English |
| last_indexed | 2024-12-13T20:32:30Z |
| publishDate | 2012-01-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLoS ONE |
| spelling | doaj.art-d17db0a839c247359de78f3b917840182022-12-21T23:32:24ZengPublic Library of Science (PLoS)PLoS ONE1932-62032012-01-0179e4582010.1371/journal.pone.0045820p53 codon 72 polymorphism and hematological cancer risk: an update meta-analysis.Yu WengLiqin LuGuorong YuanJing GuoZhizhong ZhangXinyou XieGuangdi ChenJun ZhangBACKGROUND: Previous studies on the association of p53 codon 72 (Arg72Pro) polymorphism with hematological malignancies risk have produced conflicting results. The purpose of this meta-analysis is to define the effect of p53 Arg72Pro polymorphism on hematological malignancies risk. METHODOLOGY/PRINCIPAL FINDINGS: Through searching PubMed databases (or hand searching) up to April 2012 using the following MeSH terms and keywords: "p53", "codon 72" "polymorphism" and "leukemia", or "lymphoma", or "myeloma", thirteen were identified as eligible articles in this meta-analysis for p53 Arg72Pro polymorphism (2,731 cases and 7, 356 controls), including nine studies on leukemia (1,266 cases and 4, 474 controls), three studies on lymphoma (1,359 cases and 2,652 controls), and one study on myeloma. The overall results suggested that p53 Arg72Pro polymorphism was not associated with hematological malignancies risk. In stratified analyses, significantly increased non-Hodgkin lymphomas risk was found in p53 Arg72Pro polymorphism heterozygote model (Arg/Pro vs. Arg/Arg: OR = 1.18, 95%CI: 1.02-1.35) and dominant model (Arg/Pro+Pro/Pro vs. Arg/Arg: OR = 1.18, 95%CI: 1.03-1.34), but no significant association was found between leukemia risk and p53 Arg72Pro polymorphism. Further studies showed no association between leukemia risk and p53 Arg72Pro polymorphism when stratified in subtypes of leukemias, ethnicities and sources of controls. CONCLUSIONS/SIGNIFICANCE: This meta-analysis indicates that the p53 Arg72Pro polymorphism may contribute to susceptibility to non-Hodgkin lymphomas.http://europepmc.org/articles/PMC3454327?pdf=render |
| spellingShingle | Yu Weng Liqin Lu Guorong Yuan Jing Guo Zhizhong Zhang Xinyou Xie Guangdi Chen Jun Zhang p53 codon 72 polymorphism and hematological cancer risk: an update meta-analysis. PLoS ONE |
| title | p53 codon 72 polymorphism and hematological cancer risk: an update meta-analysis. |
| title_full | p53 codon 72 polymorphism and hematological cancer risk: an update meta-analysis. |
| title_fullStr | p53 codon 72 polymorphism and hematological cancer risk: an update meta-analysis. |
| title_full_unstemmed | p53 codon 72 polymorphism and hematological cancer risk: an update meta-analysis. |
| title_short | p53 codon 72 polymorphism and hematological cancer risk: an update meta-analysis. |
| title_sort | p53 codon 72 polymorphism and hematological cancer risk an update meta analysis |
| url | http://europepmc.org/articles/PMC3454327?pdf=render |
| work_keys_str_mv | AT yuweng p53codon72polymorphismandhematologicalcancerriskanupdatemetaanalysis AT liqinlu p53codon72polymorphismandhematologicalcancerriskanupdatemetaanalysis AT guorongyuan p53codon72polymorphismandhematologicalcancerriskanupdatemetaanalysis AT jingguo p53codon72polymorphismandhematologicalcancerriskanupdatemetaanalysis AT zhizhongzhang p53codon72polymorphismandhematologicalcancerriskanupdatemetaanalysis AT xinyouxie p53codon72polymorphismandhematologicalcancerriskanupdatemetaanalysis AT guangdichen p53codon72polymorphismandhematologicalcancerriskanupdatemetaanalysis AT junzhang p53codon72polymorphismandhematologicalcancerriskanupdatemetaanalysis |